Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background/aim: Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain. In this study, we aimed to investigate the efficacy of preoperative nutritional status using the Global Leadership Initiative on Malnutrition (GLIM) criteria as a prognostic factor in patients receiving adjuvant S-1 chemotherapy for BTC.

Patients And Methods: In this retrospective study, excluding intrahepatic cholangiocarcinoma, we evaluated 58 patients who underwent curative surgery for BTC at Kobe University from 2013 to 2022, followed by adjuvant S-1 chemotherapy. Nutritional status was classified by GLIM criteria into normal/moderate and severe malnutrition groups. Overall (OS) and recurrence-free (RFS) survival were analyzed using Kaplan-Meier and Cox proportional hazards models.

Results: Of the 58 patients, 3.4% had no malnutrition, 72.5% had moderate malnutrition, and 24.1% had severe malnutrition. Patients with severe malnutrition had significantly worse 5-year OS (24.7% 52.5%, =0.0014) and RFS (34.3% 52.0%, =0.0066). Severe malnutrition was an independent prognostic factor for poorer OS (hazard ratio=3.40, 95% confidence interval=1.46-7.94; =0.0047) and RFS (hazard ratio=2.48, 95% confidence interval=1.07-5.76; =0.035). No significant difference in S-1 completion rates was observed.

Conclusion: Severe malnutrition, as defined by GLIM criteria, is a poor prognostic factor in patients with BTCs undergoing adjuvant S-1 chemotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401029PMC
http://dx.doi.org/10.21873/cdp.10470DOI Listing

Publication Analysis

Top Keywords

adjuvant s-1
20
s-1 chemotherapy
20
severe malnutrition
20
glim criteria
16
prognostic factor
16
factor patients
12
criteria prognostic
8
patients
8
patients undergoing
8
undergoing adjuvant
8

Similar Publications

Background: Oral fluoropyrimidine, S-1 is the standard adjuvant chemotherapy for patients with resected pancreatic cancer (PC) in Japan. Patients experiencing early recurrence are typically treated with 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP), which are commonly used in patients with advanced PC. However, no clinical studies have compared these regimens in this particular population.

View Article and Find Full Text PDF

Background/aim: Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain.

View Article and Find Full Text PDF

Introduction: Neoadjuvant gemcitabine plus S-1 (GS) therapy for resectable pancreatic cancer has been shown to prolong overall survival significantly compared with upfront surgery. Herein, we report two opposite cases of patients with resectable pancreatic cancer who underwent distal pancreatectomy after neoadjuvant GS therapy.

Case Presentation: In Case 1, a 49-year-old female with a 12 mm tumor in the pancreatic body (cT1N0M0, cStage IA, union for international cancer control [UICC] 8th edition) underwent two courses of neoadjuvant GS therapy followed by an open distal pancreatectomy.

View Article and Find Full Text PDF

We report a rare case of a solitary metastasis in which long-term complete remission was achieved with chemotherapy alone. An 81-year-old woman underwent a right hemicolectomy and D3 lymph node dissection for ascending colon cancer. Pathological findings showed type 2, 40×20 mm, tub2>muc, pT3, int, INF b, ly1, v0, pN1(1/32), pPM0, pDM0, and fStage Ⅲa.

View Article and Find Full Text PDF

Background: Gastric cancer (GC) remains a major global health burden, particularly in East Asia, due to its high incidence, aggressive progression, and poor prognosis in advanced stages. Although surgery is the mainstay of curative treatment, outcomes for locally advanced cases remain unsatisfactory despite perioperative chemotherapy. In recent years, immune checkpoint inhibitors, especially anti-PD-1 antibodies like sintilimab, have shown promise in improving survival when combined with chemotherapy.

View Article and Find Full Text PDF